Clinical Trial

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-06-23; most recent amendment 2026-02-20.
Status change: Recruiting → Active, Not Recruiting 2025-10-24
Status change: Not Yet Recruiting → Recruiting 2023-08-04
Trial Details
NCT Number NCT05918692
Lead Sponsor Biomea Fusion Inc.
Conditions Acute Myeloid Leukemia
Enrollment 35 participants
Start Date 2023-07-26
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-23